Is FBLG or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to FibroBiologics' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -536.78% -225.12% Kyntra Bio 2,199.13% N/A -47.27%

Does the media refer more to FBLG or KYNB?

In the previous week, Kyntra Bio had 2 more articles in the media than FibroBiologics. MarketBeat recorded 6 mentions for Kyntra Bio and 4 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.25 beat Kyntra Bio's score of -0.70 indicating that FibroBiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media favor DYAI or FBLG?

In the previous week, FibroBiologics had 2 more articles in the media than Dyadic International. MarketBeat recorded 4 mentions for FibroBiologics and 2 mentions for Dyadic International. FibroBiologics' average media sentiment score of 0.25 beat Dyadic International's score of -0.50 indicating that FibroBiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative FibroBiologics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer FBLG or GNTA?

FibroBiologics currently has a consensus price target of $73.00, suggesting a potential upside of 5,307.41%. Given FibroBiologics' stronger consensus rating and higher possible upside, equities analysts plainly believe FibroBiologics is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, FBLG or GNTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FibroBiologics N/A N/A -$18.65M -$5.19 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is FBLG or GNTA more profitable?

Genenta Science's return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -536.78% -225.12% Genenta Science N/A N/A N/A

Does the media prefer YARW or FBLG?

In the previous week, FibroBiologics had 3 more articles in the media than Yarrow Bioscience. MarketBeat recorded 4 mentions for FibroBiologics and 1 mentions for Yarrow Bioscience. FibroBiologics' average media sentiment score of 0.25 beat Yarrow Bioscience's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FibroBiologics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, TVGN or FBLG?

Tevogen Bio is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.63 N/A FibroBiologics N/A N/A -$18.65M -$5.19 N/A

Is TVGN or FBLG more profitable?

Tevogen Bio's return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -468.32% FibroBiologics N/A -536.78% -225.12%

FibroBiologics (FBLG) Competitors

$1.35 -0.09 (-6.25%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$1.34 -0.01 (-1.04%)

As of 04:00 AM Eastern

Compare

FBLG vs. KYNB, DYAI, GNTA, YARW, and TVGN

Should you buy FibroBiologics stock or one of its competitors? FibroBiologics's main competitors and comparable companies include Kyntra Bio (KYNB), Dyadic International (DYAI), Genenta Science (GNTA), Yarrow Bioscience (YARW), and Tevogen Bio (TVGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does FibroBiologics compare to Kyntra Bio?

FibroBiologics (NASDAQ:FBLG) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

FibroBiologics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

In the previous week, Kyntra Bio had 2 more articles in the media than FibroBiologics. MarketBeat recorded 6 mentions for Kyntra Bio and 4 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.25 beat Kyntra Bio's score of -0.70 indicating that FibroBiologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Kyntra Bio has a net margin of 2,199.13% compared to FibroBiologics' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-536.78%	-225.12%
Kyntra Bio	2,199.13%	N/A	-47.27%

72.7% of Kyntra Bio shares are held by institutional investors. 7.3% of FibroBiologics shares are held by company insiders. Comparatively, 4.2% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

FibroBiologics currently has a consensus price target of $73.00, suggesting a potential upside of 5,307.41%. Kyntra Bio has a consensus price target of $32.50, suggesting a potential upside of 307.27%. Given FibroBiologics' higher probable upside, research analysts plainly believe FibroBiologics is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Kyntra Bio has higher revenue and earnings than FibroBiologics. FibroBiologics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A
Kyntra Bio	$6.44M	5.02	$183.45M	$45.30	0.18

Summary

Kyntra Bio beats FibroBiologics on 12 of the 16 factors compared between the two stocks.

How does FibroBiologics compare to Dyadic International?

Dyadic International (NASDAQ:DYAI) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Dyadic International presently has a consensus target price of $3.00, suggesting a potential upside of 341.63%. FibroBiologics has a consensus target price of $73.00, suggesting a potential upside of 5,307.41%. Given FibroBiologics' higher probable upside, analysts clearly believe FibroBiologics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

FibroBiologics has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. FibroBiologics' return on equity of -536.78% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
FibroBiologics	N/A	-536.78%	-225.12%

Dyadic International has higher revenue and earnings than FibroBiologics. Dyadic International is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	8.01	-$7.36M	-$0.23	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

28.0% of Dyadic International shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by insiders. Comparatively, 7.3% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dyadic International has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

In the previous week, FibroBiologics had 2 more articles in the media than Dyadic International. MarketBeat recorded 4 mentions for FibroBiologics and 2 mentions for Dyadic International. FibroBiologics' average media sentiment score of 0.25 beat Dyadic International's score of -0.50 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
FibroBiologics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Dyadic International beats FibroBiologics on 8 of the 15 factors compared between the two stocks.

How does FibroBiologics compare to Genenta Science?

FibroBiologics (NASDAQ:FBLG) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

FibroBiologics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

In the previous week, FibroBiologics had 4 more articles in the media than Genenta Science. MarketBeat recorded 4 mentions for FibroBiologics and 0 mentions for Genenta Science. FibroBiologics' average media sentiment score of 0.25 beat Genenta Science's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the media.

Company	Overall Sentiment
FibroBiologics	Neutral
Genenta Science	Neutral

Genenta Science's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-536.78%	-225.12%
Genenta Science	N/A	N/A	N/A

15.1% of Genenta Science shares are held by institutional investors. 7.3% of FibroBiologics shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

FibroBiologics currently has a consensus price target of $73.00, suggesting a potential upside of 5,307.41%. Given FibroBiologics' stronger consensus rating and higher possible upside, equities analysts plainly believe FibroBiologics is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

Summary

FibroBiologics beats Genenta Science on 6 of the 11 factors compared between the two stocks.

How does FibroBiologics compare to Yarrow Bioscience?

Yarrow Bioscience (NASDAQ:YARW) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

83.8% of Yarrow Bioscience shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by insiders. Comparatively, 7.3% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, FibroBiologics had 3 more articles in the media than Yarrow Bioscience. MarketBeat recorded 4 mentions for FibroBiologics and 1 mentions for Yarrow Bioscience. FibroBiologics' average media sentiment score of 0.25 beat Yarrow Bioscience's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
FibroBiologics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Yarrow Bioscience currently has a consensus target price of $58.00, indicating a potential upside of 46.84%. FibroBiologics has a consensus target price of $73.00, indicating a potential upside of 5,307.41%. Given FibroBiologics' higher probable upside, analysts clearly believe FibroBiologics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Yarrow Bioscience has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

FibroBiologics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Yarrow Bioscience's return on equity of -84.40% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
FibroBiologics	N/A	-536.78%	-225.12%

FibroBiologics has lower revenue, but higher earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	185.03	-$26.48M	-$14.64	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

Summary

FibroBiologics beats Yarrow Bioscience on 8 of the 15 factors compared between the two stocks.

How does FibroBiologics compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Tevogen Bio is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

In the previous week, FibroBiologics had 4 more articles in the media than Tevogen Bio. MarketBeat recorded 4 mentions for FibroBiologics and 0 mentions for Tevogen Bio. FibroBiologics' average media sentiment score of 0.25 beat Tevogen Bio's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tevogen Bio	Neutral
FibroBiologics	Neutral

Tevogen Bio's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
FibroBiologics	N/A	-536.78%	-225.12%

Tevogen Bio currently has a consensus price target of $100.00, suggesting a potential upside of 1,368.43%. FibroBiologics has a consensus price target of $73.00, suggesting a potential upside of 5,307.41%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts plainly believe FibroBiologics is more favorable than Tevogen Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Tevogen Bio has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Summary

FibroBiologics beats Tevogen Bio on 9 of the 11 factors compared between the two stocks.

Get FibroBiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBLG vs. The Competition

Export

Metric	FibroBiologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.59M	$4.01B	$7.36B	$12.81B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-0.26	11.69	270.56	24.05
Price / Sales	N/A	1,414.76	639.15	105.26
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	0.73	17.37	11.21	6.40
Net Income	-$18.65M	-$22.72M	$3.46B	$347.95M
7 Day Performance	18.42%	2.52%	1.74%	1.49%
1 Month Performance	89.61%	9.81%	7.34%	5.15%
1 Year Performance	-88.93%	57.46%	26.13%	17.01%

FibroBiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBLG FibroBiologics	2.259 of 5 stars	$1.35 -6.3%	$73.00 +5,307.4%	-88.5%	$9.59M	N/A	N/A	10
KYNB Kyntra Bio	2.8957 of 5 stars	$7.00 +2.7%	$32.50 +364.6%	N/A	$28.42M	$4.62M	0.15	570
DYAI Dyadic International	3.0599 of 5 stars	$0.75 -3.5%	$3.00 +298.4%	-20.1%	$27.44M	$3.09M	N/A	7	Gap Up
GNTA Genenta Science	0.4493 of 5 stars	$1.16 -7.9%	N/A	-67.2%	$27.36M	N/A	N/A	7
YARW Yarrow Bioscience	2.7953 of 5 stars	$41.72 +0.8%	$58.00 +39.0%	N/A	$27.21M	$570K	N/A	30	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBLG) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FibroBiologics (FBLG) Competitors

FBLG vs. KYNB, DYAI, GNTA, YARW, and TVGN

How does FibroBiologics compare to Kyntra Bio?

Summary

How does FibroBiologics compare to Dyadic International?

Summary

How does FibroBiologics compare to Genenta Science?

Summary

How does FibroBiologics compare to Yarrow Bioscience?

Summary

How does FibroBiologics compare to Tevogen Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FibroBiologics (FBLG) Competitors

FBLG vs. KYNB, DYAI, GNTA, YARW, and TVGN

How does FibroBiologics compare to Kyntra Bio?

Which has more risk & volatility, FBLG or KYNB?

Does the media refer more to FBLG or KYNB?

Is FBLG or KYNB more profitable?

Do institutionals & insiders hold more shares of FBLG or KYNB?

Do analysts prefer FBLG or KYNB?

Which has higher earnings & valuation, FBLG or KYNB?

Summary

How does FibroBiologics compare to Dyadic International?

Do analysts recommend DYAI or FBLG?

Is DYAI or FBLG more profitable?

Which has higher valuation and earnings, DYAI or FBLG?

Do institutionals and insiders hold more shares of DYAI or FBLG?

Which has more risk & volatility, DYAI or FBLG?

Does the media favor DYAI or FBLG?

Summary

How does FibroBiologics compare to Genenta Science?

Which has more volatility and risk, FBLG or GNTA?

Does the media refer more to FBLG or GNTA?

Is FBLG or GNTA more profitable?

Do insiders and institutionals believe in FBLG or GNTA?

Do analysts prefer FBLG or GNTA?

Which has stronger valuation and earnings, FBLG or GNTA?

Summary

How does FibroBiologics compare to Yarrow Bioscience?

Do insiders and institutionals have more ownership in YARW or FBLG?

Does the media prefer YARW or FBLG?

Do analysts rate YARW or FBLG?

Which has more risk and volatility, YARW or FBLG?

Is YARW or FBLG more profitable?

Which has preferable valuation and earnings, YARW or FBLG?

Summary

How does FibroBiologics compare to Tevogen Bio?

Which has better valuation and earnings, TVGN or FBLG?

Does the media prefer TVGN or FBLG?

Is TVGN or FBLG more profitable?

Do analysts recommend TVGN or FBLG?

Which has more risk & volatility, TVGN or FBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools